Study guide

17.2 Movement Disorders & Cognitive Impairment

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

17.2 Movement Disorders & Cognitive Impairment

Key Takeaways Explain This Topic AI

Parkinson's disease is diagnosed clinically by bradykinesia (progressive decrement in amplitude and speed during repetitive movements) combined with asymmetric 4–6 Hz resting tremor or lead-pipe/cogwheel rigidity, driven by loss of dopaminergic neurons in the substantia nigra pars compacta and alpha-synuclein Lewy bodies.

Levodopa combined with a dopa-decarboxylase inhibitor (co-careldopa or co-beneldopa) is the most potent motor therapy, but precipitates motor fluctuations ('wearing off') and peak-dose dyskinesias within 3–5 years; dopamine agonists (pramipexole, ropinirole) carry a high risk of impulse control disorders (gambling, hypersexuality) and somnolence.

Atypical parkinsonian syndromes (Parkinson-Plus) are distinguished by early atypical signs: vertical supranuclear gaze palsy and early backward falls in PSP (hummingbird sign); severe autonomic failure, cerebellar ataxia, and stridor in MSA (hot cross bun sign); asymmetric alien limb and cortical sensory loss in CBD.

Dementia with Lewy Bodies (DLB) presents with fluctuating cognition, detailed visual hallucinations, spontaneous parkinsonism, and REM sleep behaviour disorder; administration of typical or atypical neuroleptics can precipitate fatal neuroleptic malignant syndrome or irreversible extrapyramidal collapse.

Alzheimer's disease features early episodic memory failure with medial temporal atrophy, treated with acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine; monitor for bradycardia) or memantine (NMDA receptor antagonist); frontotemporal dementia presents before age 65 with prominent personality changes, disinhibition, and knife-blade frontotemporal atrophy.

Last updated: September 2026

Movement disorders and neurodegenerative dementias represent a major domain in MRCP(UK) Part 1. Candidates must master clinical diagnostic criteria for Parkinson's disease, the pharmacology and long-term complications of dopaminergic medications, the distinguishing features of Parkinson-Plus syndromes, and the differential diagnosis and evidence-based pharmacotherapy of neurodegenerative cognitive disorders.

  • 1. Parkinson's Disease: Neuropathology & Clinical Phenotype
  • Neuropathology & Pathogenesis

Dopaminergic Depletion: Progressive degeneration of pigmented neuromelanin-containing dopaminergic projection neurons within the substantia nigra pars compacta (SNpc) , causing profound loss of striatal dopamine in the putamen and caudate nucleus. Motor symptoms manifest when approximately 60–70% of SNpc neurons are lost.

Histopathological Hallmark: Intraneuronal Lewy bodies —eosinophilic cytoplasmic inclusions composed of aggregated, misfolded α-synuclein and ubiquitin.

Braak Staging Hypothesis: Pathology originates decades before motor symptoms in the enteric nervous system and olfactory bulb, ascending via the vagus nerve to the medulla, pons, and midbrain (SNpc), before finally invading the cerebral cortex.

Clinical Diagnostic Criteria (UK Brain Bank Criteria)

Diagnosis requires the presence of bradykinesia PLUS at least one of the following three cardinal motor signs:

Bradykinesia (Essential / Sine Qua Non): Slowness of movement initiation and progressive reduction in speed and amplitude during repetitive movements (e.g. finger tapping, hand opening/closing, foot tapping).

Muscular Rigidity: Resistance to passive joint movement throughout the entire range of motion ("lead-pipe rigidity"), or with superimposed tremor ("cogwheel rigidity"). Rigidity is reinforced by voluntary movement of the contralateral limb ( Froment's manoeuvre ).

Resting Tremor: Characteristic 4–6 Hz "pill-rolling" tremor , asymmetric at onset, present at rest, suppressed during purposeful voluntary movement, and reinforced during mental calculation (e.g. counting backwards) or walking.

Postural Instability: Late finding in idiopathic PD (impaired postural recovery on the pull test); early postural instability with falls (<1–2 years) strongly indicates an atypical parkinsonian syndrome .

Classical Examination & Motor Features

Cranial Signs: Masked facies (hypomimia), reduced blink rate, hypophonia (quiet monotone speech), drooling of saliva (sialorrhoea from impaired swallowing).

Motor & Gait: Micrographia (handwriting becoming progressively smaller and cramped), festinant shuffling gait with reduced unilateral arm swing, difficulty initiating gait (freezing), hesitation, and en bloc turning (requiring multiple steps to turn).

Glabellar Tap Reflex (Myerson's Sign): Repetitive tapping on the forehead between the eyebrows fails to extinguish blinking (normal subjects habituate after 3–5 taps).

Non-Motor Features (Often Predating Motor Signs)

Hyposmia / Anosmia: Present in >90% of patients, frequently predating motor deficits by 5–10 years.

REM Sleep Behaviour Disorder (RBD): Loss of normal motor atonia during REM sleep, causing vivid, violent dream-enactment behaviours (kicking, punching); strong predictor of phenoconversion to an α-synucleinopathy.

Autonomic Dysfunction: Severe intractable constipation, orthostatic hypotension, erectile dysfunction, and urinary urgency/frequency.

Neuropsychiatric Symptoms: Depression, anxiety, apathy, cognitive slowing (bradyphrenia), and late visual hallucinations.

2. Medical Pharmacotherapy of Parkinson's Disease

Drug Class & Agents Mechanism of Action Clinical Role & Indications Characteristic Toxicities & High-Yield Exam Pearls

Levodopa + DDCI ; (Co-careldopa / Co-beneldopa) Metabolic precursor of dopamine; crosses blood-brain barrier via LNAA transporter. Co-formulated with peripheral dopa-decarboxylase inhibitor (carbidopa or benserazide) Most efficacious motor agent ; first-line therapy, especially in elderly patients (>65 years) or those with significant motor impairment - Nausea, vomiting, postural hypotension; - Long-term motor complications (at 3–5 years) : End-of-dose "wearing-off", unpredictable "on-off" fluctuations, and peak-dose dyskinesias (choreoathetosis)

Dopamine Receptor Agonists ; (Pramipexole, Ropinirole, Rotigotine patch) Non-ergot direct agonists at striatal D2 and D3 dopamine receptors First-line monotherapy or adjunct, often favoured in younger patients (<65 years) to postpone levodopa motor complications - Impulse Control Disorders (ICDs) in 15–20%: pathological gambling, hypersexuality, binge eating, punding (driven by D3 stimulation in nucleus accumbens); - Excessive daytime somnolence & sudden sleep attacks (driving warning); - Peripheral ankle oedema, hallucinations

Ergot-Derived Dopamine Agonists ; (Cabergoline, Bromocriptine) Direct dopamine receptor stimulation with ergot alkaloid structure Rarely used due to severe fibrotic complications - Fibrotic reactions via 5-HT2B agonism : Retroperitoneal, pulmonary/pleural, and cardiac valvular fibrosis (requires baseline and serial echocardiography, ESR, creatinine, CXR)

MAO-B Inhibitors ; (Rasagiline, Selegiline, Safinamide) Irreversibly inhibit central monoamine oxidase type B, preventing dopamine degradation in the striatum Mild symptomatic benefit as monotherapy in early disease, or adjunct to reduce "wearing-off" - Minimal cheese reaction risk at therapeutic doses (MAO-A spared); - Insomnia, headache, nausea, postural hypotension

COMT Inhibitors ; (Entacapone, Opicapone, Tolcapone) Inhibit catechol-O-methyltransferase, preventing peripheral degradation of levodopa to 3-OMD, extending levodopa half-life Adjunct strictly combined with levodopa to smooth out motor fluctuations and "wearing-off" - Entacapone harmlessly discolours urine reddish-brown ; - Diarrhoea (can be severe/delayed); - Tolcapone causes fatal acute hepatic failure (rarely used, requires intensive LFT monitoring)

NMDA Antagonist ; (Amantadine) Weak uncompetitive NMDA receptor antagonist; promotes dopamine release Used primarily as add-on therapy to suppress levodopa-induced dyskinesias - Livedo reticularis (mottled purplish skin discolouration), ankle oedema, confusion, hallucinations

Anticholinergics ; (Trihexyphenidyl, Orphenadrine) Central muscarinic receptor antagonists Useful for prominent resting tremor in younger patients (<60 years) - Confusion, memory impairment, acute urinary retention, dry mouth, blurred vision, acute angle-closure glaucoma; contraindicated in elderly

3. Atypical Parkinsonian Syndromes (Parkinson-Plus)

The Parkinson-Plus syndromes are neurodegenerative conditions that present with parkinsonism but exhibit distinct clinical, pathological, and neuroimaging features with poor response to levodopa:

Diagnostic Feature Progressive Supranuclear Palsy (PSP) Multiple System Atrophy (MSA) Corticobasal Degeneration (CBD) Vascular Parkinsonism

Underlying Neuropathology 4-repeat (4R) Tauopathy ; neurofibrillary tangles in basal ganglia and brainstem α-Synucleinopathy ; glial cytoplasmic inclusions in oligodendrocytes 4-repeat (4R) Tauopathy ; astrocytic plaques and ballooned cortical neurons Multiple subcortical lacunar strokes and arteriolosclerotic leukoaraiosis

Cardinal Clinical Manifestations - Early backward falls (<1 year) ; - Vertical supranuclear gaze palsy (downward saccades impaired first); - Axial rigidity > limb rigidity; - Retrocollis (neck extension); - Profound frontal apathy - Early severe autonomic failure (orthostatic BP drop >= 30/15 mmHg, urinary incontinence, erectile dysfunction); - Cerebellar ataxia (MSA-C) or parkinsonism (MSA-P); - Laryngeal stridor (risk of sudden death) - Marked asymmetric presentation ; - Limb apraxia (ideomotor); - Alien limb phenomenon ; - Cortical sensory loss (astereognosis); - Focal dystonia, myoclonus - "Lower-body parkinsonism" ; - Wide-based "magnetic" gait; - Upright posture, preserved arm swing; - Sparing of facial expression; - Absence of resting tremor

Ocular Motor Signs Impaired downward voluntary saccades; preserved doll's head (oculocephalic) reflex Nystagmus, broken smooth pursuit, normal vertical saccades Ocular motor apraxia Normal ocular motility

Levodopa Responsiveness Poor or transient (<20%) Poor or absent (<10%); can trigger severe orofacial dystonia Poor or absent Minimal or absent

Diagnostic Neuroimaging (MRI) Midbrain tegmental atrophy with preserved pons: "Hummingbird" or "Penguin" sign on sagittal T1; "Mickey Mouse" sign on axial midbrain Atrophy of pons, middle cerebellar peduncles; "Hot cross bun" sign on axial T2; hyperintense putaminal rim Asymmetric frontoparietal cortical atrophy contralateral to the more affected limb Extensive bilateral subcortical and periventricular white matter T2/FLAIR hyperintensities

4. Neurodegenerative Dementia Subtypes

Dementia Subtype Primary Pathology Distinctive Clinical Phenotype Neuroimaging & Biomarkers Guideline-Directed Management

Alzheimer's Disease Extracellular β-amyloid (Aβ42) plaques and intracellular hyperphosphorylated tau neurofibrillary tangles Insidious onset; early prominent impairment of episodic memory (repeating questions, misplacing items), progressing to executive dysfunction, visuospatial disorientation, dysnomia, and apraxia MRI: Bilateral medial temporal lobe and hippocampal atrophy .; CSF: Decreased Aβ42, increased total tau and phospho-tau Acetylcholinesterase inhibitors (AChEIs) : Donepezil, Rivastigmine, Galantamine (mild-to-moderate). Memantine (NMDA antagonist; moderate-to-severe). Perform baseline ECG: AChEIs cause bradycardia/heart block

Dementia with Lewy Bodies (DLB) Intraneuronal α-synuclein Lewy bodies in cortex, limbic structures, and brainstem Classic core tetrad:; 1. Fluctuating cognition with marked variations in attention/alertness; 2. Recurrent well-formed visual hallucinations (people, animals); 3. Spontaneous motor parkinsonism (within 1 year of cognitive onset); 4. REM sleep behaviour disorder ¹²³I-FP-CIT SPECT ( DaTscan ) reveals reduced striatal dopamine transporter uptake.; MRI: Relative preservation of medial temporal lobes AChE inhibitors (donepezil, rivastigmine) highly effective for hallucinations and cognitive fluctuations.; CRITICAL CONTRAINDICATION: Severe neuroleptic sensitivity ; avoid typical/atypical antipsychotics (risk of fatal rigidity/NMS)

Vascular Dementia Cerebrovascular disease: multiple cortical infarcts, strategic lacunes, or subcortical ischemic leukoaraiosis Stepwise cognitive decline , temporal link to stroke/TIA events; prominent early executive dysfunction (planning, processing speed), preserved recognition memory; focal pyramidal signs MRI: Extensive periventricular white matter hyperintensities, multi-infarct status, lacunes Intensive vascular risk factor reduction: antihypertensives, high-intensity statin, antiplatelet therapy, smoking cessation, diabetes management

Frontotemporal Dementia (Pick's Disease) 3R/4R tau inclusions (Pick bodies) or TDP-43 proteinopathies Early onset (<65 years) .; - Behavioural variant (bvFTD): Personality changes, social disinhibition , apathy, loss of empathy, dietary hyperorality (craving sweets), compulsive stereotypies.; - Language variants: Primary progressive aphasia MRI: Marked, circumscribed, asymmetric "knife-blade" atrophy of frontal and anterior temporal lobes Supportive, behavioral strategies, SSRIs for compulsions/hyperphagia.; AChE inhibitors are INEFFECTIVE and may worsen agitation